Your browser doesn't support javascript.
loading
Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma.
Hu, Yue; Pan, Tao; Cai, Xi; He, Quan-Sheng; Zheng, Yu-Bao; Huang, Ming-Sheng; Jiang, Zai-Bo; Chen, Jun-Wei; Wu, Chun.
Afiliación
  • Hu Y; Department of Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Pan T; State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Cai X; Department of Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • He QS; Department of Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Zheng YB; State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Huang MS; Department of Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Jiang ZB; Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Chen JW; Department of Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Wu C; Department of Interventional Radiology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
J Gastrointest Oncol ; 14(4): 1837-1848, 2023 Aug 31.
Article en En | MEDLINE | ID: mdl-37720446
Background: Transarterial chemoembolization (TACE) is the standard treatment for hepatocellular carcinoma (HCC); the value of its combination with systemic therapy is worthy of further exploration. This study aimed to investigate the efficacy and safety of TACE combined with tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) in the treatment of unresectable HCC. Methods: In this retrospective observational, single-center study, 147 patients with unresectable HCC were divided into a TACE group (n=98) and a non-TACE group (n=49) based on whether TACE was performed during TKI plus ICI therapy. The survival outcomes and adverse events (AEs) of the two groups were compared. Results: Data from patients with unresectable HCC who received TKI plus ICI treatment between July 2017 and April 2020 were collected. The median intrahepatic tumor size was 8.7 cm [interquartile range (IQR), 5.9-12.4 cm]. At data cut-off, overall survival (OS) of the TACE group was significantly longer than that of the non-TACE group (19.5 and 10.8 months, respectively, P=0.005). In the high-risk cohort (with main or contralateral portal vein tumor thrombi and/or bile duct invasion and/or a tumor burden >50% of liver), the OS of the TACE group was still longer than that of the non-TACE group (14.9 and 8.7 months, respectively, P=0.031). Major AEs were tolerated in both groups, and there was no significant difference in their incidence (34.7% and 30.6%, respectively, P=0.621). Conclusions: TACE treatment combined with TKI plus ICI regime resulted in longer OS than treatment with TKI plus ICI alone for patients with unresectable HCC.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Gastrointest Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Gastrointest Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: China